|
| Status |
Public on Aug 01, 2011 |
| Title |
KOPTK1 GSI treated 12hrs |
| Sample type |
RNA |
| |
|
| Source name |
KOPTK1 cell line
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: KOPTK1
tumor type: T-cell acute lymphoblastic leukemia
agent: CmpdE
|
| Treatment protocol |
Mock-treated cultures included DMSO vehicle at 0.01% final concentration for 12 hours. Gamma-secretase inhibitor (GSI)-treated cultures included compound E (CmpdE; (S,S)- 2-[2-(3,5-Difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide) (Calbiochem) at 1.0uM final concentration for 12 hours.
|
| Growth protocol |
Cells were cultured in RPMI 1640 media supplemented with 10% fetal bovine serum, sodium pyruvate, pen/strep, and L-glutamine in a humidified 5% CO2 atmosphere at 37C.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Trizol extraction of total RNA was performed according to the manufacturer's instructions.
|
| Label |
biotin
|
| Label protocol |
Ten micrograms of total RNA was used to generate biotin labeled cRNA according to standard Affymetrix protocols.
|
| |
|
| Hybridization protocol |
Standard Affymetrix protocol
|
| Scan protocol |
Standard Affymetrix protocol
|
| Description |
KOPTK1 CmpdE
CP060329H133P06.CEL
|
| Data processing |
dChip software was used to perform interarray brightness normalization by the invariant set method followed by calculation of PM/MM difference model-based expression values.
|
| |
|
| Submission date |
Jun 14, 2011 |
| Last update date |
Aug 01, 2011 |
| Contact name |
Andrew P Weng |
| E-mail(s) |
[email protected]
|
| Phone |
604-675-8136
|
| Fax |
604-877-0712
|
| Organization name |
BC Cancer Agency
|
| Department |
Pathology
|
| Lab |
Terry Fox Laboratory
|
| Street address |
675 West 10th Ave
|
| City |
Vancouver |
| State/province |
BC |
| ZIP/Postal code |
V5Z 1L3 |
| Country |
Canada |
| |
|
| Platform ID |
GPL570 |
| Series (1) |
| GSE29959 |
Human T-ALL cell line response to inhibition of Notch signaling |
|
